Together, these data show that CS-E is a bona fide inhibitor of the Wnt/beta-catenin signaling pathway in EMT6 and 4T1 breast cancer cells, and that CS-E treatment interferes with Wnt3a-stimulated receptor activation at the cell surface. The gene discussed is WNT3A; the disease is breast carcinoma.